THROMBOGENICS

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Established: 1985-01-01

Employees: -

Market Cap: -

Website: http://www.thrombogenics.com

Clinical Trials

A Study to Evaluate THR-317 Treatment for Macular Telangiectasia Type 1 (MacTel 1)

Phase 2

Completed

Conditions: Retinal Telangiectasis
Idiopathic Juxtafoveal Retinal Telangiectasia

Interventions: Drug: THR-317 8mg

First Posted Date: 2018-09-13

Last Posted Date: 2020-09-02

Lead Sponsor: ThromboGenics

Target Recruit Count: 8

Registration Number: NCT03669393

Locations: 🇫🇷
Hôpital Lariboisière, Paris, France
🇫🇷
Hôpital Cochin, Paris, France
🇨🇭
Hôpital Ophtalmique Jules-Gonin, Lausanne, Switzerland

A Study to Evaluate the Safety of THR-687 in Subjects With Diabetic Macular Edema (DME)

Phase 1

Completed

Conditions: Diabetes Mellitus
Diabetic Macular Edema
Diabetic Retinopathy

Interventions: Drug: THR-687 dose level 3
Drug: THR-687 dose level 2
Drug: THR-687 dose level 1

First Posted Date: 2018-09-12

Last Posted Date: 2020-01-22

Lead Sponsor: ThromboGenics

Target Recruit Count: 12

Registration Number: NCT03666923

Locations: 🇺🇸
Center for Retina and Macular Disease, Winter Haven, Florida, United States
🇺🇸
Midwest Eye Institute, Indianapolis, Indiana, United States
🇺🇸
Palmetto Retinal Center, West Columbia, South Carolina, United States

and more 4 locations

A Study to Evaluate the Safety of THR-149 in Subjects With Diabetic Macular Edema (DME)

Phase 1

Completed

Conditions: Diabetes Mellitus
Diabetic Macular Edema
Diabetic Retinopathy

Interventions: Drug: THR-149 dose level 1
Drug: THR-149 dose level 2
Drug: THR-149 dose level 3

First Posted Date: 2018-04-30

Last Posted Date: 2019-06-13

Lead Sponsor: ThromboGenics

Target Recruit Count: 12

Registration Number: NCT03511898

Locations: 🇺🇸
Sierra Eye Associates, Reno, Nevada, United States
🇺🇸
Retinal Research Center, PLLC, Austin, Texas, United States
🇺🇸
Retina Research Institute of Texas, Abilene, Texas, United States

and more 4 locations

A Study to Evaluate the Safety and Efficacy of THR-317 for the Treatment of Diabetic Macular Oedema (DME)

Phase 2

Completed

Conditions: Macular Edema
Diabetic Retinopathy

Interventions: Drug: Anti-PlGF recombinant monoclonal antibody, 4mg dose
Drug: Anti-PlGF recombinant monoclonal antibody, 8mg dose

First Posted Date: 2017-03-06

Last Posted Date: 2018-04-17

Lead Sponsor: ThromboGenics

Target Recruit Count: 49

Registration Number: NCT03071068

A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

Phase 2

Terminated

Conditions: Posterior Vitreous Detachment
Diabetic Retinopathy
Disease Progression

Interventions: Drug: ocriplasmin 0.0625mg
Drug: ocriplasmin 0.125mg
Drug: Sham injection

First Posted Date: 2016-02-12

Last Posted Date: 2020-12-16

Lead Sponsor: ThromboGenics

Target Recruit Count: 48

Registration Number: NCT02681809

A Retrospective Chart Review of Patients Treated With Ocriplasmin for Symptomatic VMA

Completed

Conditions: Symptomatic Vitreomacular Adhesion (VMA)

First Posted Date: 2014-07-18

Last Posted Date: 2015-07-09

Lead Sponsor: ThromboGenics

Target Recruit Count: 134

Registration Number: NCT02193945

Locations: 🇺🇸
Southeastern Retina Associates, P.C., Kingsport, Tennessee, United States
🇺🇸
Retinal Diagnostic Center, Campbell, California, United States
🇺🇸
Orange County Retina Medical Group, Santa Ana, California, United States

and more 21 locations

Ocriplasmin Research to Better Inform Treatment (ORBIT)

Completed

Conditions: Symptomatic Vitreomacular Adhesion

First Posted Date: 2014-03-06

Last Posted Date: 2016-06-21

Lead Sponsor: ThromboGenics

Target Recruit Count: 540

Registration Number: NCT02079883

Locations: 🇺🇸
Retina Vitreous Associates of FL, St. Petersburg, Florida, United States
🇺🇸
Sarasota Retina Institute, Sarasota, Florida, United States
🇺🇸
Georgia Retina, Decatur, Georgia, United States

and more 107 locations

Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole

Phase 3

Completed

Conditions: Vitreomacular Adhesion Including Macular Hole

Interventions: Other: Sham injection
Drug: Ocriplasmin

First Posted Date: 2011-09-07

Last Posted Date: 2016-03-14

Lead Sponsor: ThromboGenics

Target Recruit Count: 220

Registration Number: NCT01429441

Locations: 🇺🇸
Texas Retina Associates, Dallas, Texas, United States
🇺🇸
Retina Associates of Cleveland, Cleveland, Ohio, United States
🇺🇸
Vitroretinal Consultants, Houston, Texas, United States

and more 21 locations

Single IV Administration of TB-402 for Prophylaxis of Venous Thromboembolic Events (VTE) After Total Hip Replacement Surgery

Phase 2

Completed

Conditions: Prophylaxis of Venous Thromboembolic Events

Interventions: Drug: Rivaroxaban
Drug: TB-402

First Posted Date: 2011-04-29

Last Posted Date: 2012-08-23

Lead Sponsor: ThromboGenics

Target Recruit Count: 632

Registration Number: NCT01344954

Locations: 🇦🇹
KRANKENHAUS DES BARMHER.SCHW.Linz, Linz, Austria
🇷🇺
Federal State Healthcare Institution: Clinical Hospital #122 named after L.G. Sokolov under the Federal Medical-Biological Agency of Russia, Saint-Petersburg, Russian Federation
🇧🇪
ZNA Antwerpen Locatie Middelheim, Antwerpen, Belgium

and more 33 locations

Follow-up Study to Assess Visual Function in Subset of Patients Who Have Previously Participated in the TG-MV-006 and TG-MV-007 Ocriplasmin Studies

Completed

Conditions: Symptomatic Vitreomacular Adhesion

Interventions: Drug: placebo
Drug: ocriplasmin

First Posted Date: 2011-02-02

Last Posted Date: 2017-01-13

Lead Sponsor: ThromboGenics

Target Recruit Count: 24

Registration Number: NCT01287988

Locations: 🇧🇪
Universitaire Ziekenhuizen K.U. Leuven, Leuven, Belgium
🇺🇸
Retinal Consultants of Houston, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy